©The Author(s) 2022.
World J Clin Cases. Aug 6, 2022; 10(22): 7785-7793
Published online Aug 6, 2022. doi: 10.12998/wjcc.v10.i22.7785
Published online Aug 6, 2022. doi: 10.12998/wjcc.v10.i22.7785
Table 1 Baseline characteristics of patients with papillary adenoma
| No. | Sex | Age in yr | Tumor size in mm | Biopsy pathology |
| 1 | M | 59 | 20 | Tubular adenoma |
| 2 | M | 60 | 15 | Tubular adenoma and HGD |
| 3 | M | 49 | 32 | Adenomatoid hyperplasia and LGD |
| 4 | M | 44 | 20 | Tubular adenoma |
| 5 | M | 50 | 10 | Neuroendocrine tumor (stage G1) |
| 6 | F | 86 | 40 | HGD |
| 7 | M | 56 | 43 | Tubular adenoma and HGD |
| 8 | F | 52 | 20 | Tubular adenoma |
- Citation: Liu SZ, Chai NL, Li HK, Feng XX, Zhai YQ, Wang NJ, Gao Y, Gao F, Wang SS, Linghu EQ. Prospective single-center feasible study of innovative autorelease bile duct supporter to delay adverse events after endoscopic papillectomy. World J Clin Cases 2022; 10(22): 7785-7793
- URL: https://www.wjgnet.com/2307-8960/full/v10/i22/7785.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i22.7785